Christopher Bulow
Founder at ResistanceBio, Inc.
Profile
Christopher Bulow founded Viosera Therapeutics Inc. in 2016, where he worked as Chief Operating Officer.
Dr. Bulow also founded resistanceBio, Inc., where he worked as Chief Financial Officer & Director.
Christopher Bulow active positions
| Companies | Position | Start |
|---|---|---|
ResistanceBio, Inc.
 ResistanceBio, Inc. BiotechnologyHealth Technology ResistanceBio, Inc. is a company that focuses on overcoming treatment-resistant cancer. The company is based in San Carlos, CA. The company's mission is to defeat this type of cancer by developing a novel class of multi-targeted oncology treatments called Resistance Suppressing Therapy (REST). ResistanceBio was founded by Nicholas Goldner and Christopher Bulow, with Nicholas Goldner serving as the CEO since incorporation. | Founder | - |
Former positions of Christopher Bulow
| Companies | Position | End |
|---|---|---|
Viosera Therapeutics Inc.
 Viosera Therapeutics Inc. Miscellaneous Commercial ServicesCommercial Services Viosera Therapeutics Inc. engages in the research and develop services that predict and block drug resistance in cancer and bacteria. The company was founded by Christopher Bulow and Nicholas Goldner and is headquartered in St. Louis, MO. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Viosera Therapeutics Inc.
Viosera Therapeutics Inc. Miscellaneous Commercial ServicesCommercial Services Viosera Therapeutics Inc. engages in the research and develop services that predict and block drug resistance in cancer and bacteria. The company was founded by Christopher Bulow and Nicholas Goldner and is headquartered in St. Louis, MO. | Commercial Services |
ResistanceBio, Inc.
ResistanceBio, Inc. BiotechnologyHealth Technology ResistanceBio, Inc. is a company that focuses on overcoming treatment-resistant cancer. The company is based in San Carlos, CA. The company's mission is to defeat this type of cancer by developing a novel class of multi-targeted oncology treatments called Resistance Suppressing Therapy (REST). ResistanceBio was founded by Nicholas Goldner and Christopher Bulow, with Nicholas Goldner serving as the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Christopher Bulow
